SCHEMBL23733477

SCHEMBL23733477

CCc1ccc2c(n1)CCN(C(=O)[C@H]1CCCCN1)C2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 2/20 0.45
CDK4 P11802 2/20 0.45
CDK2 P24941 2/20 0.45
CDK7 P50613 2/20 0.45
CDK9 P50750 2/20 0.45
CDK6 Q00534 2/20 0.45
PARP1 P09874 1/20 0.44
P2RX7 Q99572 1/20 0.42
CGAS Q8N884 1/20 0.39
GABRG2 P18507 6/20 0.38
GABRB3 P28472 6/20 0.38
GABRA5 P31644 6/20 0.38
TLR9 Q9NR96 1/20 0.38
TLR8 Q9NR97 1/20 0.38
TLR7 Q9NYK1 1/20 0.38
KCNH2 Q12809 2/20 0.37
KEAP1 Q14145 1/20 0.36
CCR4 P51679 3/20 0.36
DPP4 P27487 1/20 0.35
DPP8 Q6V1X1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23733478 0.83 CDK1 (0.43) CDK1CDK4CDK2CDK7CDK9
SCHEMBL21414370 0.81 GABRG2 (0.44) CDK1CDK4GABRG2GABRB3GABRA5
SCHEMBL23733473 0.80 CDK4 (0.44) CDK1CDK4CDK2CDK7CDK9
SCHEMBL20203529 0.80 CDK1 (0.45) CDK1CDK4CDK2CDK7CDK9
SCHEMBL23733474 0.80 CDK1 (0.45) CDK1CDK4CDK2CDK7CDK9
SCHEMBL21414438 0.77 GABRG2 (0.41) CDK1CDK4GABRG2GABRB3GABRA5
SCHEMBL20203569 0.76 CDK1 (0.40) CDK1CDK4CDK2CDK7CDK9
SCHEMBL21414397 0.75 GABRG2 (0.44) GABRG2GABRB3GABRA5KCNH2
SCHEMBL23733476 0.74 POLB (0.43) CDK1CDK4GABRG2GABRB3GABRA5
SCHEMBL21414440 0.73 KDR (0.42) CDK1CDK4CDK2CDK7CDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11084814-B2 Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof TEIJIN PHARMA LIMITED (JP) 2021-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11084814-B2 Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof CDK4, CDK6, CDK16 CDK1 8/4885CDK4 1/4885CDK2 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.